Anfray, C., Mainini, F., Digifico, E., Maeda, A., Sironi, M., Erreni, M., Anselmo, A.,
Ummarino, A., Gandoy, S., Expósito, F., et al. (2021). Intratumoral combination therapy with
poly(I:C) and resiquimod synergistically triggers tumor-associated macrophages for effective
systemic antitumoral immunity. J Immunother Cancer. 9, e002408.
Byun, C. S., Hwang, S., Woo, S. H., Kim, M. Y., Lee, J. S., Lee, J. I., Kong, J. H., Bae, K. S.,
Park, I. H., Kim, S. H., and Eom, Y. W. (2020). Adipose Tissue-Derived Mesenchymal Stem
Cells Suppress Growth of Huh7 Hepatocellular Carcinoma Cells via Interferon (IFN)-betaMediated JAK/STAT1 Pathway in vitro. Int J Med Sci. 17, 609-619.
Corrigan, F., Mander, K. A., Leonard, A. V., and Vink, R. (2016). Neurogenic inflammation
after traumatic brain injury and its potentiation of classical inflammation. J Neuroinflammation.
13, 264.
Decker, T., Stockinger, S., Karaghiosoff, M., Müller, M., and Kovarik, P. (2002). IFNs and
STATs in innate immunity to microorganisms. J Clin Invest. 109, 1271-77.
Dunn, G. P., Bruce, A. T., Sheehan, K. C., Shankaran, V., Uppaluri, R., Bui, J. D., Diamond,
M. S., Koebel, C. M., Arthur, C., White, J. M., et al. (2005). A critical function for type I
interferons in cancer immunoediting. Nat Immunol. 6, 722-729.
51
Dunn, G. P., Koebel, C. M., and Schreiber, R. D. (2006). Interferons, immunity and cancer
immunoediting. Nat Rev Immunol. 6, 836-848.
Douglas, S. D., and Leeman, S. E. (2011). Neurokinin-1 receptor: functional significance in the
immune system in reference to selected infections and inflammation. Ann N Y Acad Sci. 1217,
83-95.
Dempoya, J., Matsumiya, T., Imaizumi, T., Hayakari, R., Xing, F., Yoshida, H., Okumura, K.,
& Satoh, K. (2012). Double-Stranded RNA Induces Biphasic STAT1 Phosphorylation by both
Type I Interferon (IFN)-Dependent and Type I IFN-Independent Pathways. J Virol. 86,1276012769.
Deng, R., Zuo, C., Li, Y., Xue, B., Xun, Z., Guo, Y., Wang, X., Xu, Y., Tian, R., Chen, S., et
al. (2020). The innate immune effector ISG12a promotes cancer immunity by suppressing the
canonical Wnt/beta-catenin signaling pathway. Cell Mol Immunol. 17, 1163-1179.
Donisi, C., Puzzoni, M., Ziranu, P., Lai, E., Mariani, S., Saba, G., Impera, V., Dubois, M.,
Persano, M., Migliari, M., et al. (2021a). Immune Checkpoint Inhibitors in the Treatment of
HCC. Front Oncol. 10: 601240.
52
Deng, H., Kan, A., Lyu, N., He, M., Huang, X., Qiao, S., Li, S., Lu, W., Xie, Q., Chen, H., et
al. (2021b). Tumor-derived lactate inhibit the efficacy of lenvatinib through regulating PD-L1
expression on neutrophil in hepatocellular carcinoma. J Immunother Cancer. 9, e002305
Engel, M. A., Becker, C., Reeh, P. W., and Neurath, M. F. (2011). Role of sensory neurons in
colitis: increasing evidence for a neuroimmune link in the gut. Inflamm Bowel Dis.17, 1030–
1033.
Eishingdrelo, H., and Kongsamut, S. (2013). Minireview: Targeting GPCR Activated ERK
Pathways for Drug Discovery. Curr Chem Genom Transl Med. 7, 9-15.
Ferlay, J., Soerjomataram, I., Dikshit, R., Eser, S., Mathers, C., Rebelo, M., Parkin, D. M.,
Forman, D., and Bray, F. (2015). Cancer incidence and mortality worldwide: sources, methods
and major patterns in GLOBOCAN 2012. Int J Cancer. 136, E359-386.
Gleason, N. R., Gallos, G., Zhang, Y., and Emala, C. W. (2010). Propofol Preferentially Relaxes
Neurokinin Receptor-2-induced Airway Smooth Muscle Contraction in Guinea Pig Trachea.
Anesthesiology. 112, 1335-1344.
Griebel, G., and Holsboer, F. (2012). Neuropeptide receptor ligands as drugs for psychiatric
diseases: the end of the beginning? Nat Rev Drug Discov. 11, 462-478.
53
Galon, J., Bruni, D. (2019). Approaches to treat immune hot, altered and cold tumours with
combination immunotherapies. Nat Rev Drug Discov. 18, 197-218.
Hauger, R.L., Olivares-Reyes, J.A., Dautzenberg, F.M., Lohr, J.B., Braun, S., and Oakley, R.H.
(2012). Molecular and cell signaling targets for PTSD pathophysiology and pharmacotherapy.
Neuropharmacology. 62, 705-714.
Ivashkiv, L.B. (2018). IFNγ: signalling, epigenetics and roles in immunity, metabolism, disease
and cancer immunotherapy. Nat Rev Immunol. 18, 545-58.
Jiang, W., Lu, Z., He, Y., and Diasio, R.B. (1997). Dihydropyrimidine dehydrogenase activity
in hepatocellular carcinoma: implication in 5-fluorouracil-based chemotherapy. Clin Cancer
Res. 3, 395-399.
Jin, Y., Hong, H. S., and Son, Y. (2015). Substance P enhances mesenchymal stem cellsmediated immune modulation. Cytokine. 71, 145–153.
Jin, Y., Sun, Z., Geng, J., Yang, L., Song, Z., Song, H., Wang, J., and Tang, J. (2019). IL-21
reinvigorates exhausted natural killer cells in patients with HBV-associated hepatocellular
carcinoma in STAT1-depedent pathway. Int Immunopharmacol. 70, 1-8.
54
Kato, A., Miyazaki, M., Ambiru, S., Yoshitomi, H., Ito, H., Nakagawa, K., Shimizu, H.,
Yokosuka, O., and Nakajima, N. (2001). Multidrug resistance gene (MDR-1) expression as a
useful prognostic factor in patients with human hepatocellular carcinoma after surgical
resection. J Surg Oncol. 78, 110-115.
Kitamura, H., Kobayashi, M., Wakita, D., and Nishimura, T. (2012). Neuropeptide Signaling
Activates Dendritic Cell-Mediated Type 1 Immune Responses through Neurokinin-2 Receptor.
The Journal of Immunology. 188, 4200–4208.
Kant, V., Mahapatra, P. S., Gupta, V., Bag, S., Gopalakrishnan, A., Kumar, D., and Kumar, D.
(2021). Substance P, a Neuropeptide, Promotes Wound Healing via Neurokinin-1 Receptor. Int
J Low Extrem Wounds. 2021.Advance online publication.
Llovet, J. M., Kelley, R. K., Villanueva, A., Singal, A. G., Pikarsky, E., Roayaie, S., Lencioni,
R., Koike, K., Zucman-Rossi, J., and Finn, R. S. (2021). Hepatocellular carcinoma. Nat Rev
Dis Primers. 7, 6.
Mostafa, G.A., Reda, S.M., Abd El-Aziz, M.M., and Ahmed, S.A. (2008). Sputum neurokinin
A in Egyptian asthmatic children and adolescents: relation to exacerbation severity. Allergy.
63, 1244-1247.
55
McNab, F., Mayer-Barber, K., Sher, A., Wack, A., and O'Garra, A. (2015). Type I interferons
in infectious disease. Nat Rev Immunol. 15, 87-103.
Munoz, M., Rosso, M., and Covenas, R. (2019). Neurokinin-1 Receptor Antagonists against
Hepatoblastoma. Cancers (Basel). 11, 1258.
Morelli, A. E., Sumpter, T. L., Rojas-Canales, D. M., Bandyopadhyay, M., Chen, Z., Tkacheva,
O., Shufesky, W. J., Wallace, C. T., Watkins, S. C., Berger, A., et al. (2020). Neurokinin-1
Receptor Signaling Is Required for Efficient Ca2+ Flux in T-Cell-Receptor-Activated T Cells.
Cell Reports. 30, 3448-3465.
Nizam, E., and Erin, N. (2018). Differential consequences of neurokinin receptor 1 and 2
antagonists in metastatic breast carcinoma cells; Effects independent of Substance P. Biomed
Pharmacother. 108, 263-270.
Ohtake, J., Kaneumi, S., Tanino, M., Kishikawa, T., Terada, S., Sumida, K., Masuko, K., Ohno,
Y., Kita, T., Iwabuchi, S., et al. (2015). Neuropeptide signaling through neurokinin-1 and
neurokinin-2 receptors augments antigen presentation by human dendritic cells. J Allergy Clin
Immunol. 136, 1690-1694.
Ohno, Y., Toyoshima, Y., Yurino, H., Monma, N., Xiang, H., Sumida, K., Kaneumi, S., Terada,
S., Hashimoto, S., Ikeo, K., et al. (2017). Lack of interleukin-6 in the tumor microenvironment
56
augments type-1 immunity and increases the efficacy of cancer immunotherapy. Cancer Sci.
108, 1959-1966.
O'Donnell, J.S., Teng, M.W.L., and Smyth, M.J. (2019). Cancer immunoediting and resistance
to T cell-based immunotherapy. Nat Rev Clin Oncol. 16, 151-167.
Okada, N., Sugiyama, K., Shichi, S., Shirai, Y., Goto, K., Sakane, F., Kitamura, H., and
Taketomi, A. (2022).
Combination therapy for hepatocellular carcinoma with diacylglycerol
kinase alpha inhibition and anti-programmed cell death-1 ligand blockade. Cancer Immunol
Immunother. 71, 889-903.
Severini, C., Improta, G., Falconieri-Erspamer, G., Salvadori, S., and Erspamer, V. (2002). The
tachykinin peptide family. Pharmacol Rev. 54, 285-322.
Sculptoreanu, A., Aura Kullmann, F., and De Groat, W.C. (2008a). Neurokinin 2 receptormediated activation of protein kinase C modulates capsaicin responses in DRG neurons from
adult rats. Eur J Neurosci. 27, 3171-3181.
Sun, J., Ramnath, R.D., Tamizhselvi, R., and Bhatia, M. (2008b). Neurokinin A engages
neurokinin-1 receptor to induce NF-κB-dependent gene expression in murine macrophages:
implications of ERK1/2 and PI 3-kinase/Akt pathways. Am J Physiol Cell Physiol. 295, C679C691.
57
Schelfhout, V., Van De Velde, V., Maggi, C., Pauwels, R., and Joos, G. (2009). The effect of
the tachykinin NK2 receptor antagonist MEN11420 (nepadutant) on neurokinin A-induced
bronchoconstriction in asthmatics. Ther Adv Respir Dis. 3, 219-226.
Steinhoff, M.S., von Mentzer, B., Geppetti, P., Pothoulakis, C., and Bunnett N.W. (2014).
Tachykinins and Their Receptors: Contributions to Physiological Control and the Mechanisms
of Disease. Physiol Rev. 94, 265-301.
Suvas S. (2017). Role of Substance P Neuropeptide in Inflammation, Wound Healing, and
Tissue Homeostasis. J Immunol. 199, 1543–1552.
Sangro, B., Sarobe, P., Hervas-Stubbs, S., and Melero, I. (2021). Advances in immunotherapy
for hepatocellular carcinoma. Nat Rev Gastroenterol Hepatol. 18, 525-543.
Tuluc, F., Lai, J.P., Kilpatrick, L.E., Evans, D.L., and Douglas, S.D. (2009). Neurokinin 1
receptor isoforms and the control of innate immunity. Trends Immunol. 30, 271-276.
Trinchieri, G. (2010). Type I interferon: friend or foe? J Exp Med. 207, 2053-2063.
Toyoshima, Y., Kitamura, H., Xiang, H., Ohno, Y., Homma, S., Kawamura, H., Takahashi, N.,
Kamiyama, T., Tanino, M., and Taketomi, A. (2019). IL6 Modulates the Immune Status of the
58
Tumor Microenvironment to Facilitate Metastatic Colonization of Colorectal Cancer Cells.
Cancer Immunol Res. 7, 1944-1957.
Waldman, A.D., Fritz, J.M., and Lenardo, M.J. (2020a). A guide to cancer immunotherapy:
from T cell basic science to clinical practice. Nat Rev Immunol. 20, 651-668.
Wang, Z., Chen, T., Lin, W., Zheng, W., Chen, J., Huang, F., and Xie, X. (2020b). Functional
tumor specific CD8 + T cells in spleen express a high level of PD-1. Int Immunopharmacol. 80,
106242.
Xiang, H., Toyoshima, Y., Shen, W., Wang, X., Okada, N., Kii, S., Sugiyama, K., Nagato, T.,
Kobayashi, H., Ikeo, K., et al. (2022). IFN-α/β-mediated NK2R expression is related to the
malignancy of colon cancer cells. Cancer Sci. 113, 2513-2525.
Ziche, M., Morbidelli, L., Geppetti, P., Maggi, C. A., and Dolara, P. (1991). Substance P
induces migration of capillary endothelial cells: a novel NK-1 selective receptor mediated
activity. Life Sci. 48, PL7–PL11.
Zou, J., Zhuang, M., Yu, X., Li, N., Mao, R., Wang, Z., Wang, J., Wang, X., Zhou, H., Zhang,
L., et al. (2018). MYC inhibition increases PD-L1 expression induced by IFN-gamma in
hepatocellular carcinoma cells. Mol Immunol. 101, 203-209.
59
Zhang, S., and Lin, X. (2019). CARMA3: Scaffold Protein Involved in NF-κB Signaling. Front
Immunol. 10, 176.
60
...
論文の公開元へ
